Literature DB >> 24175665

Expression of HPV-related biomarkers and grade of cervical intraepithelial lesion at treatment.

George Valasoulis1, Sofia-Melina Stasinou, Maria Nasioutziki, Antonis Athanasiou, Maria Zografou, Aris Spathis, Aristotelis Loufopoulos, Petros Karakitsos, Evangelos Paraskevaidis, Maria Kyrgiou.   

Abstract

OBJECTIVES: New human papillomavirus (HPV)-related biomarkers may allow better identification of clinically significant lesions that warrant excision and, conversely, identification of the false positive cases that have been overreported by traditional techniques. The aim of this study was to investigate how the expression of several HPV-related biomarkers correlates to the severity of the lesion at treatment.
DESIGN: Prospective observational study.
SETTING: University Hospital (2009-2011). POPULATION: All women submitted for excisional treatment.
METHODS: A liquid-based cytology sample was obtained before treatment and was tested for HPV typing, mRNA E6 & E7 with NASBA or flow cytometry and p16. All women had histological diagnosis in the form of excisional cone (gold standard). MAIN OUTCOME MEASURES: Correlation of HPV biomarker positivity rates to the grade of the lesion at treatment histology.
RESULTS: Two hundred women were recruited: 23 were found to have negative histology (11.5%), 79 (39.5%) CIN1, 50 (25.0%) CIN2 and 48 (24.0%) CIN3. All biomarkers (HPV DNA typing, HR HPV, single HPV 16/18, mRNA E6 & E7 expression and p16) revealed an increased linear positivity rate with increasing severity and grade of the lesion (chi-squared test for trend p < 0.05). This was stronger for HPV (all and high-risk) followed by mRNA with NASBA, flow cytometry, HPV 16/18 and ultimately p16 immunostaining.
CONCLUSIONS: The linear correlation between various HPV-related biomarkers and the grade of the lesion suggests that these biomarkers may prove to be useful in the prediction of CIN grade and, as a result, the need for treatment.
© 2013 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  HPV DNA tests; RNA; cervical intra-epithelial neoplasia; conization; gynecologic oncology; messenger; p16INK4 protein

Mesh:

Substances:

Year:  2014        PMID: 24175665     DOI: 10.1111/aogs.12298

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Quality evaluation of cone biopsy specimens obtained by large loop excision of the transformation zone.

Authors:  Aristoteles Mauricio Garcia Ramos; Erika Souza Garcia Ramos; Helena Lucia Barroso Dos Reis; Ricardo Bueno de Rezende
Journal:  J Clin Med Res       Date:  2015-02-09

2.  Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women.

Authors:  George Valasoulis; Abraham Pouliakis; George Michail; Christine Kottaridi; Aris Spathis; Maria Kyrgiou; Evangelos Paraskevaidis; Alexandros Daponte
Journal:  Cancers (Basel)       Date:  2020-05-05       Impact factor: 6.639

Review 3.  Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Ana Cristina L Macedo; João Carlos N Gonçalves; Daniela Vicente Bavaresco; Antonio José Grande; Napoleão Chiaramonte Silva; Maria Inês Rosa
Journal:  J Oncol       Date:  2019-06-11       Impact factor: 4.375

Review 4.  The Role of p16/Ki-67 Immunostaining, hTERC Amplification and Fibronectin in Predicting Cervical Cancer Progression: A Systematic Review.

Authors:  Septimiu Toader Voidăzan; Caterina Dianzani; Mădălina Aurelia Husariu; Bíborka Geréd; Sabin Gligore Turdean; Cosmina Cristina Uzun; Zsolt Kovacs; Florin Francisc Rozsnyai; Nicoleta Neagu
Journal:  Biology (Basel)       Date:  2022-06-23

5.  Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study.

Authors:  George Valasoulis; Georgios Michail; Abraham Pouliakis; Georgios Androutsopoulos; Ioannis G Panayiotides; Maria Kyrgiou; Alexandros Daponte; Evangelos Paraskevaidis
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.